The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 4:48 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 4:48 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.
Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.
OPKO Health (OPK) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.
Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.
Align (ALGN) Extends Invisalign G8 Availability Worldwide
by Zacks Equity Research
Align's (ALGN) latest evolution in biomechanics is set to improve treatment predictability for frequently treated case types.
Can Cooper Cos. (COO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Cooper Companies (COO) Unit Gets a Boost From New Buyout
by Zacks Equity Research
The Cooper Companies (COO) arm's buyout drives its growing portfolio of medical products, which revolves around clinic and practice-based women's healthcare
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Cooper Companies (COO) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter earnings reflect weak segmental performance. However, it exceeds expectation as it witnesses faster-than-anticipated recovery.
Cooper Cos. (COO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of 1.61% and 0.38%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cooper Cos. (COO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
PDCO vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. COO: Which Stock Is the Better Value Option?
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Why Is Cooper Cos. (COO) Up 9.3% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dental Market Picks Up Pace Amid COVID-19: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on potentially strong three stocks in the dental space that have shown promise during the pandemic.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
The Cooper (COO) Soars: Stock Adds 5.4% in Session
by Zacks Equity Research
The Cooper (COO) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect dismal segmental performance. However, it exceeded expectation as it witnessed faster-than-anticipated recovery.
Cooper Cos. (COO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of 44.30% and 7.81%, respectively, for the quarter ended July 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter performance is likely to reflect weak performance by CVI and CSI.
Earnings Preview: Cooper Cos. (COO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.